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ABSTRACT 
Background: Gastrointestinal stromal tumors (GISTs) are characterized by oncogenic KIT mutations 
that cluster in two exon 11 hotspots. The aim of this study was to develop a single, sensitive, 
quantitative digital droplet PCR (ddPCR) assay for the detection of common exon 11 mutations in 
both GIST tumor tissue and in circulating tumor DNA (ctDNA) isolated from GIST patients’ plasma. 
Methods: A ddPCR assay was designed using two probes that cover both hotspots. Available archival 
FFPE tumor tissue from 27 consecutive patients with known KIT exon 11 mutations and 9 randomly 
selected patients without exon 11 mutations were tested. Plasma samples were prospectively 
collected in a multicenter bio-databank from December 2014. CtDNA was analyzed of 22 patients 
with an exon 11 mutation and a baseline plasma sample. 
Results: The ddPCR assay detected the exon 11 mutation in 21 of 22 tumors with exon 11 mutations 
covered by the assay. Mutations in ctDNA were detected at baseline in 13 of 14 metastasized 
patients, but in only 1 of 8 patients with localized disease. In serial plasma samples from 11 patients 
with metastasized GIST, a decrease in mutant droplets was detected during treatment. According to 
RECIST 1.1, 10 patients had radiological treatment response and one patient stable disease. 
Conclusion: A single ddPCR assay for the detection of multiple exon 11 mutations in ctDNA is a 
feasible, promising tool for monitoring treatment response in patients with metastasized GIST and 
should be further evaluated in a larger cohort. 
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INTRODUCTION 
Gastrointestinal stromal tumors (GISTs) are rare malignancies of the gastrointestinal tract [1]. GIST is 
known to have driver single nucleotide variants, deletions and insertions (further referred to as 
mutations) in genes encoding the tyrosine kinase receptors KIT and PDGFRα. These occur in 
respectively 80% and 10% of GIST patients [2, 3]. In untreated GIST patients, the most frequent 
mutations are in KIT exon 11 (70%) coding for the juxta-membrane domain, and KIT exon 9 (10% of 
patients), coding for the extracellular domain of the receptor [4]. Around 80% of the mutations in 
KIT exon 11 cluster in two hotspot regions of approximately 25 base pairs within a 100 base-pair 
range of each other [5].  
Therapy consists of surgery and/or treatment with one of several selective tyrosine kinase 
inhibitors (TKIs). Adjuvant treatment with a TKI is based on Miettinen’s risk classification which takes 
the size of the tumor, location and mitotic index into account [6]. Independently of the Miettinen 
classification, there is also a difference in recurrence risk between GISTs with different KIT and 
PDGFRα mutations [7]. First line treatment for locally advanced or metastatic GISTs consists of 
imatinib (400mg daily), a selective inhibitor of the KIT tyrosine kinase [8]. Almost all patients with 
exon 11 mutated GIST respond to imatinib treatment, whereas exon 9 mutated GISTs have lower 
response rates. A large meta-analysis of 1,640 patients showed that bi-daily imatinib 400 mg is more 
effective than once daily dosing in KIT exon 9 mutated patients [9]. Resistance to imatinib treatment 
is usually the result of one or multiple secondary mutations that develop during treatment [10, 11].  
Second and third line treatment, with respectively sunitinib and regorafenib, also showed 
differential response rates that correlated with the primary mutational status of the tumor [12-14].  
Molecular diagnostic testing of relevant predictive biomarkers, including KIT and PDGFRα, is 
becoming routine practice in clinical decision-making. Mutation detection is routinely performed on 
pre-treatment tumor biopsies or resection specimens. For the detection of mutations a variety of 
methods are used, including as Sanger sequencing, pyro-sequencing, next generation sequencing 
(NGS) and high-resolution-melting (HRM) analysis with reflex sequencing [15]. These techniques are 
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expensive, time consuming and require sufficient amounts of DNA (>100 ng) and a sufficient 
percentage of neoplastic cells (>5-20%). In some cases, no representative tumor material is available 
for molecular testing. Alternative methods for mutation detection, ideally also allowing serial non-
invasive measurements, are urgently needed.  
 Interestingly, recent advantages in molecular pathology enable the detection of tumor 
specific mutations in circulating tumor DNA (ctDNA) extracted from blood plasma [16]. CtDNA can be 
used to define targets for selective therapy in both untreated and TKI-resistant non-small-cell-lung-
cancer (NSCLC) tumors [17, 18]. The detection of mutations in ctDNA as a predictive biomarker has 
been reported in both metastatic breast cancer (MBC) [19] and metastatic colorectal cancer (CRC) 
[20]. Finally, mutation testing in ctDNA allows monitoring of TKI treatment response, where an 
increase in mutations could predict recurrence or disease progression [18]. Sporadic reports 
describe the use of ctDNA to detect mutations in GIST patients [21-24].  
CtDNA is present in low amounts in plasma within a much more abundant background of 
non-tumor DNA (wild type) and is varying based on tumor type [25]. Highly analytical sensitive 
methods are used to detect ctDNA in plasma, these include BEAMing [26] and digital droplet PCR 
(ddPCR) [26, 27]. Both BEAMing and ddPCR assays require the use of a separate assay for each 
tumor specific mutation. In general practice, based on the mutation detected in the tumor sample, a 
unique assay for the specific mutation is designed. Recently, the use of a single ddPCR assay to 
simultaneously detect various EGFR-exon 19 deletions in the plasma of NSCLC patients was reported 
[28]. 
Given the long disease course of GIST patients and the multiple therapeutic options 
depending on mutational status of the tumor, a non-invasive test that can easily assess the presence 
of mutations is especially interesting for this patient group. Therefore, the aim of this exploratory 
study was to develop a ddPCR assay to detect most common exon 11 KIT mutations in. For the 
validation of this drop-off ddPCR assay we tested 36 formalin fixed paraffin embedded (FFPE) pre-
treatment biopsies of patients with GIST previously tested for mutations using sequencing. To 
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investigate the utility of this assay for detecting exon 11 mutations in ctDNA, plasma from 22 GIST 
patients was analyzed at baseline and at various time points during TKI treatment. 
 
MATERIALS AND METHODS 
Study design  
The reported work is part of an open-label, non-randomized, non-interventional, explorative 
multicenter study aiming to detect the most frequently occurring KIT exon 11 mutations using a 
single ddPCR assay. The assay was first tested on archival formalin-fixed paraffin-embedded (FFPE) 
tumor tissue stored at the University Medical Centre Groningen (UMCG). After validation with tumor 
tissue, this assay is tested in prospectively collected plasma samples from 22 GIST patients before 
and during treatment with a TKI. These 22 patients were treated in one of the five hospitals in the 
Dutch GIST consortium (Antoni van Leeuwenhoek, Amsterdam; Leiden University Medical Centre, 
Leiden; Erasmus University Medical Centre, Rotterdam; Radboud University Medical Centre, 
Nijmegen; University Medical Centre Groningen, Groningen). 405 plasma samples of 140 GIST 
patients before or during treatment with a TKI have been prospectively collected (Dec 2014 - Sept 
2016). Treatment, follow-up and response evaluation by CT according to RECIST 1.1, were performed 
according to (inter)national guidelines. Plasma samples were available before start and at multiple 
time points after start of a TKI for 8 patients with localized GIST and 14 patients with metastasized 
GIST. All patients had measurable disease before collection of the first plasma sample and received 
systemic treatment during the study period. Plasma samples were collected at every visit to the 
outpatient clinic. Disease evaluation was performed by CT-scans performed approximately every 3 
months. Response evaluation was performed using RECIST version 1.1 criteria by a radiologist, 
unaware of obtained ctDNA results.  
All patients gave written informed consent. The Medical Ethical Committee approved the study and 
it is registered on ClinicalTrials.gov (NCT02331914). 
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Tumor sample collection and DNA extraction  
Pre-treatment FFPE tumor biopsies for 27 consecutive patients diagnosed with exon 11 mutated 
GIST between 2012 and 2015 were retrieved from the local pathology archive at the UMCG . Nine 
GIST tumors with mutations outside KIT exon 11 from the same period were randomly selected as 
controls. FFPE samples of healthy controls were obtained from the pathology department of UMCG. 
Tumor-specific mutations were determined by routine diagnostic NGS of a gene panel with relevant 
predictive markers (version PGMv001; www.moloncopath.nl) on the IonTorrent platform (Thermo 
Fisher Scientific, Waltham, MA, USA). The analysis of some older tumors was performed using 
Sanger sequencing as reported previously [29]. 
In brief, two to four 10 µm thick sections were cut from the original FFPE blocks preceded 
and followed by a 4 µm section. After haematoxylin and eosin staining, the 4 µm slides were 
evaluated by an experienced pathologist for the presence of an area with sufficient tumor cells 
(>20%). Genomic DNA from FFPE slides was extracted using the Cobas extraction kit (Roche, Basel, 
Switzerland) and quantified using Qubit (Thermo Fisher Scientific). All molecular testing was 
performed in the CCKL/ISO15189-accredited laboratory of molecular pathology at the UMCG. All 
standard precautions were taken to avoid contamination of amplification products using separate 
laboratories for pre- and post-PCR handling. To avoid cross-contamination, a new microtome blade 
was used each time a new sample was sectioned.  
 
Next generation sequencing using IonTorrent  
Libraries were generated using an in-house panel (version PGMv001) using the IonTorrent platform. 
This panel consists of 30 primer pairs covering 11 clinically relevant genes including hotspots in exon 
9, 11, 13 and 17 of KIT and exon 12, 14 and 18 of PDGFRα (http://www.moloncopath.nl). 10 ng of 
DNA from each sample was used to prepare barcoded libraries using IonXpress barcoded adapters 
(Thermo Fisher Scientific). Libraries were combined to a final concentration of 100 pmol using the 
Ion Library Quantification Kit (Thermo Fisher Scientific), and emulsion PCR was performed using the 
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IonTorrent OneTouch TM2 system. Samples were sequenced on the IonTorrent semi-conductor 
sequencer using Ion 316 or 318 chips. Sequence reads were aligned to the 11 genes based on the 
Human Genome version 19 using Sequence Pilot v4.2.0 (JSI Medical Systems GmbH, Ettenheim, 
Germany). Also read depth and uniformity of coverage across individual amplicons were assessed. In 
data analysis the cut-off was set at mutations found in > 5% of the reads. Only non-synonymous and 
non-sense variations in coding regions were included.  
 
Drop-off ddPCR assay  
Since in 80% of the cases exon 11 mutations occur in one of the two hotspot regions, one probe 
serves as a wild type probe while the loss of signal from the second probe represents the presence 
of a mutation (Figure 1). A ddPCR assay consisting of a single set of PCR primers and two TaqMan 
probes (FAM or HEX) was designed using PrimerQuest (http://eu.idtdna.com/Primerquest) and 
purchased from IDT (Coralville, IA, USA). The primer sequences are Fwd. 5’-
CCACAGAAACCCATGTATGAAG-3’ (position c.1641-c.1662) and Rev. 5’-GAGTTTCCCAGAAACAGGC-3’ 
(position c.1746-c.1765) resulting in a PCR product of 124 base pairs covering both hotspots in KIT 
exon 11 (position c.1641-c.1765, Figure 1). The sequence of probe I (FAM) is 5’-
ACAGTGGAAGGTTGTTGAGGAGAT-3’ and probe II (HEX) 5’-ACCCAACACAACTTCCTTATGATCACA-3’. 
Temperature gradient PCRs of the primers and probes were performed to detect the optimal 
annealing temperature and resulted in an optimal PCR temperature of 60˚C.  
 
Specific ddPCR assays  
For the detection of the c.1676T>A mutation, a commercially available assay was purchased 
(dHsaCP2506828 and dHsaCP2506829, Bio-Rad, Hercules, CA, USA). The specific c.1727_1729del 
assay was designed in-house and purchased from IDT. The primer sequences are Fwd. 5-
’CCACAGAAACCCATGTATG-3’ (position c.1643-c.1661) and Rev. 5’-GCCTGTTTCTGGGAAAC-3’ 
(position c.1750-c.1766). The sequence of wild type-probe I (FAM) is 5’-
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ACCCAACACAACCTTATGATCACAAATG-3’ and mutant-probe II (HEX) 5’-
ACAGTGGAAGGTTGTTGAGGAG-3’.  
 
DdPCR analysis of DNA of pretreatment tumor biopsies  
DdPCR on tumor tissue was performed on 2 ng of genomic DNA as measured by Qubit according to 
the manufacturer’s instructions. Briefly, 11 µl ddPCR Supermix for probes, 1 µl of the ddPCR assay 
(wild type and mutation primer/probes) and genomic DNA were mixed in a final volume of 22 μl. 
Droplets were generated from 20 μl of the suspension using the QX100 Droplet generator after 
addition of 70 μl droplet generation oil (Bio-Rad). The PCR was performed on a T100 Thermal Cycler 
(Bio-Rad) using the following cycling conditions: 10 minutes at 95°C, 40 cycles of 95°C for 30 
seconds, 60°C for 1 minute followed by 98°C for 10 minutes (ramp rate 2.5°C/sec). Samples were 
transferred to the QX200 Droplet Reader (Bio-Rad) for fluorescent measurement of FAM and HEX 
probes and data were analyzed using Quantasoft software version 1.6.6. Samples were considered 
positive when 3 or more FAM/HEX positive droplets were detected, while no FAM/HEX positive 
droplets in the no-template and no single positive droplets in the wild type controls were observed. 
The fractional abundance is based on the ratio between mutant and wild type droplets after 
correction using the Poisson distribution (calculated by the Quantasoft software).  
 
Circulating tumor DNA analysis  
Plasma samples from patients treated at the UMCG were collected in EDTA tubes (vacutainer 
#367525, Becton Dickinson, Franklin Lakes, NJ, USA) and processed within 4 hours after 
venipuncture. Samples from patients from other centers were collected in cell free DNA BCT tubes 
(Streck, Omaha, NE, USA), which stabilizes blood samples for a minimum of 7 days at room 
temperature [30]. The cell free BCT tubes were sent by regular mail to the UMCG and processed on 
the day of arrival. For quantitative validation of the assay, plasma samples of five anonymous 
healthy controls were collected in the same cell free BCT tubes. 
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EDTA samples were first centrifuged for 10 minutes at 820 g to separate the lymphocytes from the 
plasma. The supernatant was transferred to a new Eppendorf tube and centrifuged at 16,000 g for 
10 minutes to separate plasma from the remaining debris. After the last centrifugation step the 
supernatant was transferred and stored at -80˚C until analysis. Cell free DNA BCT tubes were 
processed identically but with a different first centrifugation step (1,600 g). Plasma processing was 
performed in a laboratory not used for any molecular testing. 
For ctDNA isolation, samples were thawed after storage at -80°C and centrifuged for 5 minutes at 
16,000 g. DNA was extracted from plasma using the QIAamp Circulating Nucleic Acid kit. (QIAgen, 
Hilden, Germany) following manufacturers protocols. DNA from 4 ml of plasma was isolated and 
eluted in 2 x 250 µl of elution buffer. This eluate was concentrated using an Amicon filter column 
(Merck, Darmstadt, Germany). The final amount of eluate was 15-20 µl. After isolation the eluate 
was stored at 4°C until experiments were performed.  
The designed drop-off ddPCR assay was used for analysis of ctDNA. Experimental conditions were 
identical to those for analysis of tumor tissue except for the input per reaction. For analysis of ctDNA 
the maximum input (9 µl) of isolated DNA per reaction was used, each run included wild type (WT) 
and no template controls (NTC). The presence of a mutation was calculated as the fractional 
abundance.  
Quantitative L-PCR using 1 ml of cell-free plasma was performed as reported in detail previously 
[22]. The laboratory technicians who performed the ddPCR experiments were not aware of the 
mutational and clinical status of the tested patient samples.  
 
Quantitative performance of the drop-off ddPCR assay  
The sensitivity of the assay was determined using DNA from FFPE pretreatment biopsies with 
mutations in exon 11 hotspot 1 (c.1669T>C and c. 1671_1676del) and hotspot 2 (c.1727_1729del) 
with known mutation allelic frequency (MAF) determined by NGS diluted with wild type DNA. A 
significant correlation was observed between tumor DNA input as measured by NGS-MAF and 
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mutated droplet detection in three different samples (Supplementary Data S1). The limit of 
detection (LOD) of the drop-off ddPCR assay on DNA extracted from FFPE-tissue with 30 ng DNA 
input was 0.11% (not shown) and with a lower DNA input (2 ng) a maximum of 1% mutant alleles 
was still detected (see example in Supplementary Data S2).  
The limit of blank (LOB, false mutation rate) as reported earlier [31] of the ddPCR assays was 
estimated using five FFPE healthy tissue. FFPE samples were tested with an input of 2ng and 30ng 
resulting in respectively in a mean of 545 and 5345 wild type droplets and 0 false-positive droplets 
per sample (LOB = 0% for tissue DNA). To determine the LOB on plasma-derived ctDNA, cell free 
DNA was isolated from five plasma samples of healthy controls following the study extraction 
protocol and maximum input was used resulting in a mean of 791 wild type droplets and 0 false-
positive droplets (LOB = 0% for normal plasma DNA, Supplementary Data S3).  
 
RESULTS 
Mutations in KIT exon 11 in GIST FFPE tumor tissue detected using the ddPCR drop-off assay  
27 tumors with KIT exon 11 mutations were included, 17 tumors had a deletion, 1 a duplication, 4 a 
deletion/insertion and 5 had single nucleotide variants (SNV) as previously identified by sanger 
sequencing or NGS. Seventeen mutations cluster in hotspot 1, 6 in hotspot 2, one tumor had a 
deletion affecting both hotspots (sample 12) and in 3 tumors the deletion did not occur within the 
hotspots (samples 25, 26, 27, Figure 2). Using the drop-off assay, a KIT mutation was detected in 
21/27 tumors (see examples in Supplementary Data S4). Tumor 18 had a duplication and was 
considered negative in the drop-off assay, however a typical pattern of droplet distribution was seen 
(Supplementary Data S5). In 4 of the 5 negative tumors (20, 25, 26 and 27) the deletion did not allow 
annealing of the PCR-primer and therefore a PCR-product could not be generated (true negative 
tumors). Tumor 21 carried a SNV within the detection range of probe 2 and was the only true false-
negative tumor. Of 22 tumors with mutations in KIT exon 11 covered by the drop-off assay, 21 
tumors were positive resulting in a sensitivity of 95%. Analysis of the allelic frequency of mutant 
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alleles versus wild type alleles of ddPCR corroborated the NGS results (Table 1). As a negative 
control, 9 tumors without KIT exon 11 mutations were analyzed. These consisted of 4 tumors with a 
PDGFRα mutation, 2 with a KIT exon 9 mutation and 3 without any KIT/PDGFRα mutations. All 
control GIST samples were negative resulting in a specificity of 100% (Supplementary Data S6). 
 
Tumor and treatment characteristics  
Plasma samples taken before start of TKI treatment (baseline) of 22 patients with GIST were 
analyzed. Of these 22 patients, 14 had metastatic disease and 8 localized disease. Four patients with 
localized disease were planned to start with imatinib 400mg treatment in a neo-adjuvant setting 
(patient 7,9,13 and 17) and four patients underwent primary surgery. Samples of patients with 
metastatic disease were taken before start of a new line of TKI treatment (Table 2).  
 
Detection of exon 11 mutations in ctDNA with the drop-off ddPCR assay  
KIT exon 11 mutations were detected in the baseline plasma ctDNA from 13/14 patients with 
metastasized disease (Table 2). Pre-treatment tumor DNA available for 12 of these patients tested 
positive using the drop-off ddPCR assay. Plasma from one patient (patient 6) with metastasized 
disease had no detectable mutant ctDNA while a KIT mutation was detected in the pre-treatment 
tumor biopsy. In plasma ctDNA collected before start of treatment in eight patients with localized 
disease and a tumor KIT exon 11 mutation, only one patient (sample 7) had a detectable mutation in 
the ctDNA (Table 3). 
To exclude that the lack of detectable ctDNA mutations was due to low sensitivity of the 
drop-off ddPCR assay, tumor and plasma samples collected from two patients with metastasized 
disease (patient 3 and 15) during treatment with a TKI were also tested with a specific ddPCR 
mutation assay. As shown in Table 4, the mutant fractional abundance is comparable between the 
ddPCR and the specific assay. In addition, plasma samples from three different patients were tested 
using the highly sensitive analytical L-PCR technique for the detection of specific KIT exon 11 
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mutations earlier described [22] (Table 5). For this analysis, we selected eight plasma samples from 
three patients with different KIT exon 11 mutations tested with the drop-off ddPCR assay. Low level 
mutant frequencies detected with the L-PCR technique (<0.1%) were also positive in the drop-off 
samples. Of the samples that tested negative using the drop-off assay, 4/5 were also negative using 
the L-PCR technique.  
 
The detection of mutations in plasma ctDNA at different time points during treatment 
In order to monitor the presence of mutations after start of TKI treatment compared to baseline 
samples, serial plasma samples of 11 patients with metastatic disease using the ddPCR drop-off 
assay were available and analyzed. The analysis of plasma samples at 2-3 weeks after start therapy 
revealed an increase in fractional abundance in 5 out of 11 patients (Figure 3, Supplementary Data 
S7). In all available plasma samples obtained six weeks after start of treatment the fractional 
abundance decreased below the levels observed at baseline or the 2-3 weeks after start of 
treatment sample. In agreement with the loss of detection of mutant DNA, ten patients showed a 
tumor response and one patient stable disease (no. 45) on treatment with TKI according to the first 
radiological evaluation performed approximately 3 months after start of therapy.  
 
DISCUSSION 
In this study, an in-house designed single ddPCR assay was able to detect multiple mutations in KIT 
exon 11 with high sensitivity (95%) and specificity (100%) in tumor biopsies of patients with GIST. 
Sensitivity of the assay for all known KIT exon 11 mutations in GIST is lower than 95% since the 
designed assay covers 80% of the described KIT exon 11 mutations (in the described cohort 21/27 
mutations were detected resulting in a sensitivity of 77%). For LOB analysis 5 plasma samples from 
healthy individuals and 5 normal FFPE samples were analyzed. No false positive droplets were 
detected in the ddPCR analysis of these samples. As expected, due to the quality of the FFPE 
material, highly damaged DNA as well as artifactual C>T transitions the ddPCR resulted in a reduced 
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separation of wild type droplets [32]. This should be taken into account when interpreting test 
results. However, for mutation screening in freshly-processed cell-free plasma DNA, the separation 
between drop-off and wild type droplets was excellent in all samples tested in this study. Despite a 
very good LOB and a high sensitivity of 0.1%, the maximum sensitivity that can be obtained is limited 
by the input of the total number of copies of a genome. As in plasma samples the total amount of 
DNA is often close to 2ng, this input of DNA would result in a sensitivity of 1%.  
This assay enabled the detection of low-level copy mutations and the identification of mutations in 
12 of 13 cell-free plasma samples of patients with metastatic disease at baseline. DdPCR is relatively 
cheap and has a short turn-around time. Since the probe does not detect specific mutations in exon 
11 of the KIT gene, the drop-off ddPCR assay is especially suitable for predictive testing of GIST in 
case not enough tissue or neoplastic cells are available for NGS analysis or for monitoring treatment 
response in ctDNA.  
Mutation testing in ctDNA might be an alternative source for tissue biopsies particular when 
no biopsies or biopsies with insufficient neoplastic cells percentages for molecular profiling are 
available [33]. In addition, mutation analysis of ctDNA during treatment has been reported as a new 
tool for monitoring treatment response since the amount of ctDNA correlates with the volume of 
vital tumor tissue [34]. Circulating DNA in the cell-free plasma fraction originates from many 
different cells including lymphocytes and neoplastic cells [35]. Their nuclear and mitochondrial DNA 
is released into the circulation in the process of cellular destruction by apoptosis or necrosis [25]. 
Therefore, ctDNA in cell-free plasma is a very low fraction of the total amount of circulating DNA. For 
the detection of mutations in ctDNA in a high background of total plasma DNA, various detection 
assays with high analytical sensitivity have been reported including digital PCR, BEAMing, sequencing 
based methods, Ligand PCR, ARMS-PCR and PNA-clamping PCR [36]. Because the analytical 
sensitivity of NGS is around 1-5% and also requires high amounts of input DNA, NGS is at present not 
suitable for mutation screening in ctDNA from plasma in malignancies with low abundance of ctDNA. 
On the other hand, the ddPCR has been reported as a quantitative, accurate assay with high 
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analytical sensitivity [37]. Sensitivities of 0.005-0.1% for EGFR-T790M (own unreported data, [28]), 
0,1% and 0,5% for ALK-C1156Y and ALK-G1269A in lung cancer [38] and 0.025% for KRAS in CRC [39] 
are reached. 
To the best of our knowledge, this is the first time a single ddPCR assay to detect multiple 
KIT exon 11 mutations in tumor tissue and ctDNA of patients with GIST has been reported. Few other 
studies have described the use of mutational analysis of ctDNA in GIST. In a recent study, using a 
NGS platform after enrichment PCR with PNA probes, KIT mutations were detected in the plasma of 
13 out of 18 patients with localized gastric GIST [40]. With the allele specific ligation PCR assay KIT 
mutations were found in 9 out of 18 patients with active disease, furthermore mutations at low 
levels were detected in 6 out of 20 patients in complete remission[22]. Another study using BEAMing 
detected primary mutations in 5 out of 30 patients with TKI-refractory GIST (17%) [23]. Both 
BEAMing and the allele specific ligation PCR assay require the generation of specific primers/probes 
for each genomic KIT mutation. In GIST patients with localized disease and proven KIT mutations in 
the pre-treatment biopsy, our assay detected the mutations in the baseline plasma DNA in only 1 of 
8 cases. An explanation for this discrepancy is that localized tumors may not actively shed tumor 
DNA into the circulation. In other malignancies an association was reported with the detection of 
mutations in plasma and advanced stage disease [41]. 
The ddPCR drop-off assay was previously described for the detection of various clinical-
relevant deletions in exon 19 of the EGFR gene in lung cancer [28]. This ddPCR drop-off del 19 assay 
showed a sensitivity of 5-50 mutant copies in a background of 10,000 wild type copies which is 
similar to our observed sensitivity for the ddPCR drop-off assay for KIT exon 11 mutations.  
In the analysis of serial ctDNA samples, an evident rise of fractional abundance was seen 
after initiation of treatment. We hypothesized that the rise of mutational level could be due to 
increased cell death induced therapy initiation. This early response is not reported in other 
malignancies treated with TKI [42]. Our result implies that treatment response can be monitored by 
using this ddPCR assay in cell-free plasma. Similar observations were also reported using quantitative 
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L-PCR in 5 patients with advanced GIST [22]. Monitoring of treatment response has also been 
reported in anti-EGFR treated CRC using KRAS mutations [43], TKI-treated lung cancer for EGFR 
del19/L858R [44], BRAF mutated melanoma [45] and gynecologic malignancies [46] and detection of 
progression on primary TKI in ctDNA has been reported in EGFR mutated NSCLC [47] and CRC [48]. 
Since tumors evolve during treatment and secondary mutations can cause therapeutic 
resistance, a new biopsy can be required during treatment to define the actual mutational status 
[49]. This has recently been demonstrated in patients with NSCLC during treatment with EGFR-TKI. 
The EGFR TKI-resistance mutation T790M was detected in ~70% of plasma ctDNA of patients with 
advanced disease who had acquired TKI-resistance [50]. These resistant mutations could be missed 
by conventional tissue biopsy due to tumor heterogeneity [51]. In addition, repeated tumor biopsies 
have risks e.g. bleeding, perforation and infection. Thus, there is a need for less invasive techniques 
that provide information about mutational status of tumors and that can be easily performed at 
different time points during treatment. The detection of primary and secondary resistant mutations 
in ctDNA cannot be used only to monitor recurrences before clinical manifestation, but might also 
warrant a different therapeutic approach. Recently, the FDA approved the detection of the EGFR TKI 
resistant T790M mutation in plasma (June 1, 2016) as a marker for a second generation EGFR TKI 
specifically inhibiting the T790M mutation [52]. Similarly, in GIST, resistance develops during 
imatinib treatment. In 50% of patients with progressive disease, a secondary mutation, besides the 
primary KIT mutation, is detected[53]. Treatment response to standard second line therapy, 
sunitinib, differs between patients with secondary KIT exon 13/14 or exon 17/18 mutations [54]. The 
detection of secondary mutations in plasma was reported in 4 patients using pre-amplification and 
NGS. Mutant alleles were detected in a range of 0.010 – 9.385% [24]. In a study using BEAMing 
secondary mutations were detected in 11 out of 30 patients (41%) [23]. Therefore, the 
implementation of ddPCR (or other sensitive) detection assays to identify resistant KIT mutations in 
plasma ctDNA is warranted for the development of more optimal treatment strategies in patients 
with GIST treated with TKIs. 
17 
 
The detection of multiple KIT exon 11 mutations with a single ddPCR assay has high 
sensitivity and specificity. It is suitable for predictive testing of GIST in case not enough tissue or 
neoplastic cells are available for routine NGS analysis in FFPE tissue. This technique can be easily 
performed, is cost-effective and has a short turn-around-time. Therefore, this ddPCR assay might be 
especially suitable for treatment response monitoring by ctDNA analysis in plasma. Our study will be 
extended to include the monitoring of early progression based on ctDNA, which may guide early 
treatment adaptations. 
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TABLES 
 
Table 1. Tested patients with drop-off assay in relation to NGS  
results 
 
Allelic frequency Mutation 
  
Patient 
Mutant Mutant in probe 
area 
Mutation 
 ddPCR NGS 
1 44,00% 38% 1 KIT Exon 11 c.1667_1669del 
2 58,00% 61% 1 KIT Exon 11 c.1669T>C 
3 53,00% 59% 2 KIT Exon 11 c.1727_1729del 
4 41,00% 41% 1 KIT Exon 11 c.1671_1676del 
5 30,00% 27% 2 KIT Exon 11 c.1726_1728del 
6 34,00% 38% 2 KIT Exon 11 c.1727-1729delTTC 
7 42,00% 38% 1 KIT Exon 11 c.1676T>A 
8 45,00% 45% 1 KIT Exon 11 c.1669_1674del 
9 54,00% 55% 1 KIT Exon 11 c.1671_1672delinsTG 
10 40,00% 38% 1 KIT Exon 11 c.1669_1674del 
11 83,00% 80% 1 KIT Exon 11 c.1679_1680delinsAG 
12* 22,00% 28% 1,2 KIT Exon 11 c.1673_1717del 
13 24,00% 45% 1 KIT Exon 11 c.1662_1674delinsGGAAGAA 
14 88,00% 91% 1 KIT Exon 11 c.1669_1674del 
15 35,00% 34% 1 KIT Exon 11 c.1676T>A 
16 35,70% 57% 1 KIT Exon 11 c.1669_1674delTGGAAG 
17 22,30% 25% 1 KIT Exon 11 c.1669_1674del 
18$ 0,00% 11% 2 KIT Exon 11 c.1719_ 1751dup 
19 43,60% 44% 1 KIT Exon 11 c.1669T>C 
20& 0,00% 79% 1 KIT Exon 11 c.1650_1673delinsCCTTCG 
21 0,00% Sanger 2 KIT Exon 11 c.1727 T>C 
22 95,00% 86% 1 KIT Exon 11 c.1668_1679del 
23 41,00% Sanger 2 KIT Exon 11 c.1735_1737del 
24 47,00% Sanger 1 KIT Exon 11 c.1674_1715del 
25& 0,00% 41% 0 KIT Exon 11 c.1655_1660delTGTATG 
26& 0,00% 56% 0 KIT Exon 11 c.1649_1663del 
27& 0,00% 44% 0 KIT Exon 11 c.1649_1663del 
 
Detection of mutations in KIT with the ddPCR assay of pre-treatment tumor samples compared to the mutant allelic frequency as 
determined with NGS.  
*, despite a deletion partially overlapping with both hotspot areas, a signal was observed with probe 2;  
&, deletion located in the forward primer annealing site precluding amplification of the mutated allele;  
$, duplication considered negative, however a typical pattern of droplet distribution was seen.  
For representative examples see Supplementary Data S1. 
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Table 2. Plasma ctDNA analysis with drop-off ddPCR assay of GIST patients with 
metastasized disease 
Patient 
Primary GIST 
location 
Prior  
treatment 
New 
treatment Mutation 
  
Fractional 
abundance 
3 Stomach Imatinib Sunitinib KIT exon 11 c.1727_1729del 12,00% 
4 Stomach - Imatinib KIT exon 11 c.1671_1676del 0,40% 
6 Small bowel 
Imatinib 
Sunitinib 
Regorafenib 
KIT exon 11 c.1727-1729del 0,00% 
11 Small bowel - Imatinib KIT exon 11 c.1679_1680delinsAG 0,10% 
14 Stomach - Imatinib KIT exon 11 c.1669_1674del 14,20% 
15 Small bowel - Imatinib KIT exon 11 c.1676T>A 1,00% 
16 Stomach - Imatinib KIT exon 11 c.1669_1674del 1,40% 
39 Small bowel 
Imatinib 
Sunitinib 
Regorafenib 
- 
KIT exon 11 c.1676_1684del 3,00% 
40 Small bowel - Imatinib KIT exon 11 c.1668_1717delinsACCTT 7,00% 
41 Stomach - Imatinib KIT exon 11 c.1671_1715del 8,70% 
42 Stomach Imatinib Masitinib KIT exon 11 c.1670_1675del 0,90% 
43 Small bowel - Imatinib KIT exon 11 c.1676T>A 0,40% 
44 Small bowel - Imatinib KIT exon 11 c.1665_1676del 0,90% 
45 Stomach Imatinib Sunitinib KIT exon 11 c.1674_1695del 3,10% 
Plasma samples were collected before start of a new line of TKI treatment. Pre-treatment primary tumors of 12 patients 
tested positive with the drop-off assay (patient 3-16 see table 1, patient 39-43 data not shown, patient 44 and 45 were not 
tested due to lack of tumors tissue). The fractional abundance was determined using DNA input representing 4 ml plasma. 
 
Table 3. Plasma ctDNA analysis of GIST patients with localized/locally advanced disease 
Patient 
Primary GIST 
location Disease status Mutation   
Mutant 
allelic 
frequency 
7 Rectum Localized KIT exon 11 c.1676T>A 1,95% 
9 Stomach Localized KIT exon 11 c.1671_1672delinsTG 0,00% 
10 Stomach Localized KIT exon 11 c.1669_1674del 0,00% 
12 Stomach post-surgery KIT exon 11 c.1673_1717del 0,00% 
13 Stomach Localized KIT exon 11 c.1662_1674delinsGGAAGAA; 0,00% 
17 Stomach Localized KIT exon 11 c.1669_1674del 0,00% 
19 Small bowel Localized KIT exon 11 c.1669T>C 0,00% 
37 Stomach Localized KIT exon 11 c.1679 T>A 0,00% 
Primary tumors of 7 of these patients were tested positive with the assay (patient 7-19 see table 1, patient 37 data not 
shown, tumor of patient 38 was not positive). Samples were taken before start of any treatment. 
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Table 4. Correlation between the ddPCR with a mutation-specific 
assay and the drop-off assay 
Patient Type 
Fractional 
abundance drop-off 
probe 
Fractional abundance 
mutant specific 
probe 
Mutation 
3 Tumor 53% 48% c.1727_1729del 
3A Plasma 12,02% 11,60% c.1727_1729del 
3B Plasma 8,70% 7,20% c.1727_1729del 
3C Plasma 0,70% 0,72% c.1727_1729del 
15 Tumor 35% 33% c.1676T>A 
15A Plasma 0,90% 1,02% c.1676T>A 
15B Plasma 5,50% 4,90% c.1676T>A 
15C Plasma 0,00% 0,00% c.1676T>A 
 Two tumor samples and six plasma samples of two patients with metastasized disease were 
tested with a probe specifically designed for the mutation. *A = before start of treatment, *B 
= after two weeks of treatment, *C = after 6 weeks of treatment. 
 
 
Table 5. Comparison of L-PCR with ddPCR 
Patient  mutation L-PCR 
Mutation / 
wild type % 
ddPCR 
Mutation / 
wild type %  
Disease  
status 
 
7A c.1676T>A 0,0019 1,95 Localized Before start of treatment 
7B c.1676T>A 0,0024 0 Localized 1 week treatment imatinib 
7C c.1676T>A 0 0 Localized 4 week treatment imatinib 
10A c.1669_1674del 0 0 Localized Before surgical treatment 
10B c.1669_1674del 0 0 Localized 3 days after surgery 
15A c.1676T>A 0,0015 0,94 Metastasized Before start of treatment 
15B c.1676T>A 0,0012 5,60 Metastasized 2 weeks treatment with imatinib 
15C c.1676T>A 0 0 Metastasized 6 weeks treatment with imatinib 
 
To evaluate the sensitivity of our assay, multiple samples of three patients were analysed with the earlier described L-PCR technique. 
Quantitative L-PCR analysis was performed on 1 ml plasma as reported previously [Maier et al, 2013]. Four samples were scored low-level 
positive (<0,1% mutant/wild type ratio). When looked at positive/negative samples the results where –except for sample 7B- comparable 
with the ddPCR assay.  
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FIGURE LEGENDS 
Figure 1. KIT exon 11 mutation/deletion detection assay.  
A. When no mutation is present, both probes (FAM and HEX) will anneal and droplets with a dual fluorescent signal will be 
detected (coloured orange in the figure).  
B. In cases with a mutation in hotspot region I, only droplets with WT region II are detected (HEX, green signal). Also wild 
type fragments are detected (orange droplets) in the graph. 
C. Example of a case with a mutation in hotspot region II, only droplets with WT region I are detected (FAM, blue signal). 
Wild type fragments are also detected (orange droplets). 
 
Figure 2. Location of KIT exon 11 mutations in GIST tumour samples as tested with Sanger sequencing or NGS. The 
mutations are displayed relative to the actual position of the Forward and Reverse primers, the two probes (I and II) and 
PCR product. Type of mutations: red = deletion, grey = substitution, blue = deletion/insertion, orange = duplication. 
 
Figure 3. Detection of KIT exon 11 mutations using the ddPCR drop-off assay in ctDNA in patients with metastasized GIST at 
baseline (before start TKI-treatment) and 2-6 weeks after start of treatment. Mutation frequency is expressed as fractional 
abundance in % (see Supplementary Data S7). Twelve patients with metastasized GIST with both a baseline plasma sample 
as well as at least one sample collected 2-6 weeks after staring TKI treatment were selected. Both pre-treatment FFPE DNA 
(Table 1) and baseline plasma samples (Table 2) were tested with the same ddPCR. Patient 39 and 41 (Table 3) were not 
included since no follow-up plasma samples were available. 
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